SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001104659-21-076488
Filing Date
2021-06-03
Accepted
2021-06-03 17:40:30
Documents
1
Period of Report
2021-06-02

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm2118431-1_4seq1.html 4  
1 OWNERSHIP DOCUMENT tm2118431-1_4seq1.xml 4 6979
  Complete submission text file 0001104659-21-076488.txt   9072
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Issuer) CIK: 0001006281 (see all company filings)

IRS No.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 1 DEXCEL STREET OR AKIVA L3 30600000
Business Address
Oren Dan (Reporting) CIK: 0001636701 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-33357 | Film No.: 21993814

Mailing Address 1 DEXCEL STREET OR AKIVA L3 3060000
Business Address 1 DEXCEL STREET OR AKIVA L3 3060000 97246364040
Dexcel Pharma Technologies Ltd. (Reporting) CIK: 0001720007 (see all company filings)

State of Incorp.: L3 | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-33357 | Film No.: 21993815